Spanish heart transplant units consensus conference;Conferencia de consenso de los grupos Españoles de trasplante cardiaco

Revista Espanola de Cardiologia Suplementos

Volumn 7, Issue B, 2007, Pages

  Crespo Leiro, María G ^a,b   Bonet, Luis Almenar ^a   Alonso Pulpón, Luis ^a   Campreciós, Marta ^a   Castillo, José J Cuenca ^a   Galván, Luis De La Fuente ^a   Jiménez, Juan Delgado ^a   Guereta, Luis García ^a   Lorite, Nicolás Manito ^a   Maroto, Carlos ^a   Palomo, Jesús ^a   Figal, Domingo Pascual ^a   Gallé, Ernesto Lage ^a   Lambert, José L Rodríguez ^a   Minguell, Eulàlia Roig ^a   Julve, María L Sanz ^a   De Prada, José A Vázquez ^a  

^a Seccion de Insuficiencia Cardiaca   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Consensus conference; Heart transplantation

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; GANCICLOVIR; INSULIN; ISONIAZID; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ATHEROSCLEROSIS; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL EVALUATION; CLINICAL FEATURE; CONFERENCE PAPER; CONSENSUS; CYTOMEGALOVIRUS; DIABETES MELLITUS; DIVERTICULOSIS; ECHOCARDIOGRAPHY; ENDOCARDITIS; GRAFT RECIPIENT; HEART EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KAPOSI SARCOMA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVERWORT; LUNG CANCER; MYOCARDITIS; OBESITY; ORGAN DONOR; ORGANIZATION; OSTEOPOROSIS; PEDIATRICS; POSTOPERATIVE COMPLICATION; PULMONARY HYPERTENSION; SKIN CANCER; SPAIN; VIRUS INFECTION;

EID: 36049048095     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(07)75240-8     Document Type: Conference Paper

References (391)

1. Hunt SA. Taking heart -cardiac transplantation past, present, and future. N Engl J Med. 2006;355:231-5.
2. Almenar L. Registro Español de Trasplante Cardiaco. XVII Informe Oficial de la Sección de Insuficiencia Cardiaca, Trasplante Cardiaco y otras alternativas terapéuticas de la Sociedad Española de Cardiología. Rev Esp Cardiol. 2006;59:1283-91.
3. Almenar L, Alonso-Pulpón L, Crespo-Leiro MG, Arizón JM, González-Vílchez F, Palomo J, et al. Influence of donor and recipient characteristics on recipient survival: an analysis of data in the Spanish Heart Transplantation Registry. J Heart Lung Transplant. 2005;25:S58-9.
4. Taylor D, Edwards L, Boucek M, Trulock E, Waltz D, Keck B, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report -2006. J Heart Lung Transplant. 2006;25:869-79.
5. Trulock E, Edwards L, Taylor D, Boucek M, Keck B, Hertz M. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report -2005. J Heart Lung Transplant. 2005;24:956-67.
6. Hunt SA. 24th Bethesda Conference: Cardiac transplantation. J Am Coll Cardiol. 1993;22:1-64.
7. Crespo-Leiro M, Paniagua-Martín M, Muniz J, Marzoa R, Pinon P, Rodríguez J, et al. Long-term results of heart transplant in recipients older and younger than 65 years: A comparative study of mortality, rejections, and neoplasia in a cohort of 445 patients. Transplant Proc. 2005;37:4031-2.
8. McCarthy J, McCarthy P, Massad M, Cook D, Smedira N, Kasirajan V, et al. Risk factors for death after heart transplantation: does a single-center experience correlate with multicenter registries? Ann Thorac Surg. 1998;65:1574-8.
9. Borkon A, Muehlebach G, Jones P, Bresnahan DJ, Genton R, Gorton M, et al. An analysis of the effect of age on survival after heart transplant. J Heart Lung Transplant. 1999;18:668-74.
10. Favaloro R, Díez M, Bertolotti C, Gómez C, Favaloro L, Abud J, et al. Orthotopic heart transplantation in elderly patients: a 10-year experience at a single center. Transplant Proc. 2004;36:1692-94.
11. Fonarow G. How old is too old for heart transplantation? Curr Opin Cardiol. 2000;15:97-103.
12. Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates -2006. J Heart Lung Transplant. 2006;25:1024-42.
13. Nohria A, Lewis E, Stevenson L. Medical management of advanced heart failure. JAMA. 2002;287:628-40.
14. Crespo-Leiro M, Paniagua-Martín M. Tratamiento de la insuficiencia cardiaca refractaria o avanzada. Rev Esp Cardiol. 2004;57:869-83.
15. Levy D, Kenchaiah S, Larson M, Benjamin E, Kupka M, Ho K, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-402.
16. Deng M, De Meester J, Smits J, Heinecke J, Scheld H, Group. obotCOaCPiTCS. Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by a heart failure severity. BMJ. 2000;321:540-5.
17. Aaronson K, Schwartz J, Chen T, Wong K, Goin J, Mancini D. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660-7.
18. Mancini D, Eisen H, Kussmaul W, et al. Value of peak exercise oxigen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778.
19. Lim E, Large S, Wallwork J, Parameshwar J. Candidate selection for heart transplantation in the 21st Century. Curr Opin Organ Transplant. 2002;7:221-5.
20. Hunt S, Abraham W, Chin M, Feldman A, Francis G, Ganiats T, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-235.
21. Moraes D, Colucci W, Givertz M. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000;102:1718-23.
22. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:193-8.
23. Taylor D, Edwards L, Boucek M, Trulock E, Deng M, Keck B, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report -2005. J Heart Lung Transplant. 2005;24:945-55.
24. Klotz S, Deng M, Hanafy D, Schmid C, Stypmann J, Schmidt C, et al. Reversible pulmonary hypertension in heart transplant candidates -pretransplant evaluation and outcome after orthotopic heart transplantation. Eur Heart J. 2003;5:645-53.
25. Sablotzki A, Hentschel T, Gruenig E, Schubert S, Friedrich I, Muhling J, et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg. 2002;22:746-52.
26. Angel Gómez-Sánchez M, Sáenz de la Calzada C, Escribano Subías P, Francisco Delgado Jiménez J, Lázaro Salvador M, Albarrán González A, et al. Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. Eur J Heart Fail. 2004;6:615-7.
27. Salzberg S, Lachat M, Von Harbou K, Zund G, Turina M. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg. 2005;27:222-5.
28. Stobierska-Dzierzek B, Awad H, Michler R. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol. 2001;38:923-31.
29. Morgan J, John R, Weinberg A, Colletti N, Mancini D, Edwards N. Heart transplantation in diabetic recipients: A decade review of 161 patients at Columbia Presbyterian. J Thorac Cardiovasc Surg. 2004;127:1486-92.
30. Czerny M, Sahin V, Fasching P, Zuckermann A, Zimpfer D, Kilo J, et al. The impact of diabetes mellitus at the time of heart transplantation on long-term survival. Diabetologia. 2002;45:1498-508.
31. Costanzo M, Augustine S, Bourge R, Bristow M, O'Connell J, Driscoll D, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1995;92:3593-612.
32. Castro P, Bourge R, Jalil J, Martínez J. Seleccion y evaluación de pacientes candidatos a trasplante cardiaco. Rev Esp Cardiol. 1999;52:804-16.
33. Dillon T, Sullivan M, Schatzlein M, Peterson A, Scheeringa R, Clark WJ, et al. Cardiac transplantation in patients with preexisting malignancies. Transplantation. 1991;52:82-5.
34. Cimato T, Jessup M. Recipient selection in cardiac transplantation: contraindications and risk factors for mortality. J Heart Lung Transplant. 2002;21:1161-73.
35. Shapiro P, Williams D, Foray A, Gelman I, Wukich N, Sciacca R. Psychosocial evaluation and prediction of compliance problems and morbidity after heart transplantation. Transplantation. 1995;60:1462-6.
36. Adajar F, Lawless C, Malinowska K. Outcome of heart transplant in patients with renal insufficiency. J Heart Lung Transplant. 2001;20:248.
37. Loria K, Salinger M, Frohlich T, Arentzen C, Alexander JJ, Anderson R. Right lower lobectomy for pulmonary infarction before orthotopic heart transplantation. J Heart Lung Transplant. 1991;10:325-8.
38. Tzakis A, Cooper M, Dummer J, Ragni M, Ward J, Starzl T. Transplantation in HIV+ patients. Transplantation. 1990;49:354-8.
39. Hosenpud J, Pamidi S, Fiol B, Cinquegrani M, Keck B. Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using the joint ISHLT/UNOS thoracic registry. J Heart Lung Transplant. 2000;19:781-5.
40. Castella M, Tenderich G, Koerner M, Arusoglu L, El-Banayosy A, Schulz U, et al. Outcome of heart transplantation in patients previously infected with hepatitis C virus. J Heart Lung Transplant. 2001;20:595-8.
41. O'Connell J, Dec G, Goldenberg I, Starling R, Mudge G, Augustine S, et al. Results of heart transplantation for active lymphocytic myocarditis. J Heart Transplant. 1990;9:351-5.
42. Aaronson K, Patel H, Pagani F. Patient selection for left ventricular assist device therapy. Ann Thorac Surg. 2003;75 Suppl 6:S29-35.
43. Kocher A, Ankersmit J, Khazen C, Ofner P, Zuckermann A, Grimm M, et al. Effect of obesity on outcome after cardiac transplantation. Transplant Proc. 1999;31:3187-9.
44. Baron O, Trochu J, Treilhaud M, Al Habash O, Remadi J, Petit T, et al. Cardiac transplantation in patients over 60 years of age. Transplant Proc. 1999;31:75-8.
45. Baran D, Galin I, Courtney M, Correa R, Chan M, Spielvogel D, et al. Cardiac transplantation in the older recipient: excellent long-term survival based on pretransplant screening. Transplant Proc. 2003;35:2465-7.
46. John R, Lietz K, Schuster M, Mancini D, Naka Y, Oz M, et al. Older recipient age is associated with reduced alloreactivity and graft rejection after cardiac transplantation. J Heart Lung Transplant. 2001;20:212.
47. Kushwaha S, Fallon J, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997;336:267-75.
48. Srivastava R, Keck B, Bennett L, Hosenpud J. The results of cardiac retransplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. Transplantation. 2000;70:606-12.
49. John R, Chen J, Weinberg A, Oz M, Mancini D, Itescu S, et al. Long-term survival after cardiac retransplantation: a twenty-year single-center experience. J Thorac Cardiovasc Surg. 1999;117:543-55.
50. Ceriani R, Mazzoni M, Bortone F, Gandini S, Solinas C, Susini G, et al. Application of the sequential organ failure assessment score to cardiac surgical patients. Chest. 2003;123:1229-39.
51. Geppert A, Steiner A, Zorn G, Delle-Karth G, Koreny M, Haumer M, et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med. 2002;30:1987-94.
52. Geppert A, Huber K. Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Curr Opin Crit Care. 2004;10:347-53.
53. Jessup M, Brozena S. Epilogue: support devices for end stage heart failure. Cardiol Clin. 2003;21:135-9.
54. Samuels L, Darze E. Management of acute cardiogenic shock. Cardiol Clin. 2003;21:43-9.
55. Kirklin J, McGiffin D, Young J. The donor heart. En: Kirklin JK, McGiffin D, Young J, editores. Heart transplantation. Philadelphia: Churchill Livingstone; 2002. p. 293-338.
56. Baldwin J, Anderson J, Boucek M, Bristow M, Jennings B, Ritsch MJ, et al. 24th Bethesda conference: Cardiac transplantation. Task Force 2: Donor guidelines. J Am Coll Cardiol. 1993;22:15-20.
57. Zaroff J, Rosengard B, Armstrong W, Babcock W, D'Alessandro A, Dec G, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation. 2002;106:836-41.
58. Zaroff J, Babcock W, Shiboski S, Solinger L, Rosengard B. Temporal changes in left ventricular systolic function in heart donors: results of serial echocardiography. J Heart Lung Transplant. 2003;22:383-8.
59. De Mattos A, Head M, Everett J, Hosenpud J, Hershberger R, Cobanoglu A, et al. HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high-confidence-level serological DR typing is used. Transplantation. 1994;57:626-30.
60. Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. N Engl J Med. 1994;330:816-9.
61. Morgan J, John R, Weinberg A, Kherani A, Colletti N, Vigilance D, et al. Prolonged donor ischemic time does not adversely affect long-term survival in adult patients undergoing cardiac transplantation. J Thorac Cardiovasc Surg. 2003;126:1624-33.
62. Del Rizzo D, Menkis A, Pflugfelder P, Novick R, McKenzie F, Boyd W, et al. The role of donor age and ischemic time on survival following orthotopic heart transplantation. J Heart Lung Transplant. 1999;18:310-9.
63. Michel P, Vial R, Rodriguez C, Ferrera R. A comparative study of the most widely used solutions for cardiac graft preservation during hypothermia. J Heart Lung Transplant. 2002;21:1030-9.
64. Garlicki M. May preservation solution affect the incidence of graft vasculopathy in transplanted heart? Ann Transplant. 2003;8:19-24.
65. Faggian G, Forni A, Mazzucco A. Donor organ preservation in high-risk cardiac transplantation. Transplant Proc. 2004;36:617-9.
66. Rodeheffer R, Naftel D, Stevenson L, Porter C, Young J, Miller L, et al. Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A multi-institutional study. Cardiac Transplant Research Database Group. Circulation. 1996;94:2883-9.
67. Bourge R, Kirklin J, Thomas K, Czerska B, Lee F, Kasper E, et al. The emergence of co-morbid diseases impacting survival after cardiac transplantation, a ten year multi-institutional experience. J Heart Lung Transplant. 2001;20:167-8.
68. Solomon N, McGiven J, Alison P, Ruygrok P, Haydock D, Coverdale H, et al. Changing donor and recipient demographics in a heart transplantation program: influence on early outcome. Ann Thorac Surg. 2004;77:2096-102.
69. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant. 1990;9:587-93.
70. Rodríguez E. The pathology of heart transplant biopsy specimens: revisiting the 1990 ISHLT working formulation. J Heart Lung Transplant. 2003;22:3-15.
71. Winters G, Marboe C, Billingham M. The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant. 1998;17:754-60.
72. Crespo-Leiro M, Veiga-Barreiro A, Doménech N, Paniagua M, Piñón P, González-Cuesta M, et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management and the value of C4d for diagnosis. Am J Transplant. 2005;5:2560-4.
73. Rodríguez E, Skojec D, Tan C, Zachary A, Kasper E, Conte J, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5: 2778-85.
74. Duong Van Huyen J, Fornes P, Guillemain R, Amrein C, Chevalier P, Latremouille C, et al. Acute vascular humoral rejection in a sensitized cardiac graft recipient: diagnostic value of C4d immunofluorescence. Hum Pathol. 2004;35:385-8.
75. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710-20.
76. Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Reinsmoen NL, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25:153-9.
77. Billingham M. Cardiac transplant pathology. En: Hammond EH, editor. Solid organ transplantation pathology. Philadelphia: WB Saunders; 1994. p. 69-91.
78. Joshi A, Masek M, Brown B, Weiss L, Billingham M. "Quilty" revisited: A 10-year perspective. Hum Pathol. 1995;26:547-57.
79. Moloney E, Egan J, Kelly P, Wood A, Cooper LJ. Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant. 1995;24:1103-10.
80. Barbers R. Role of transplantation (lung, liver, and heart) in sarcoidosis. Clin Chest Med. 1997;18:865-74.
81. Aull M, Buell J, Trofe J, First M, Alloway R, Hanaway M, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation. 2004;78:1676-82.
82. Caves P, Schulz W, Dong EJ, Stinson E, Shumway N. New instrument for transvenous cardiac biopsy. Am J Cardiol. 1974;33:264-7.
83. Winters G, Loh E, Schoen F. Natural history of focal moderate cardiac allograft rejection. Is treatment warranted? Circulation. 1995;91:1975-80.
84. Mills R, Naftel D, Kirklin J, Van Bakel A, Jaski B, Massin E, et al. Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J Heart Lung Transplant. 1997;16:813-21.
85. Mehra M, Uber P, Vivekananthan K, Solis S, Scott R, Park M, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol. 2002;40:1609-14.
86. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-7.
87. Calvino-Santos R, Crespo-Leiro M, Vázquez-Rodríguez J, Salgado-Fernández J, Vázquez-González N, Paniagua-Martín M, et al. Deep vein thrombosis after transfemoral endomyocardial biopsy in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:643-4.
88. Tucker PN, Jin B, Gaos C, Radovancevic B, Frazier O, Wilansky S. Flail tricuspid leaflet after multiple biopsies following orthotopic heart transplantation: echocardiographic and hemodynamic correlation. J Heart Lung Transplant. 1994;13:466-72.
89. Chan M, Giannetti N, Kato T, Kornbluth M, Oyer P, Valantine H, et al. Severe tricuspid regurgitation after heart transplantation. J Heart Lung Transplant. 2001;20:709-17.
90. Vázquez de Prada J. Revisión crítica de la biopsia endomiocárdica en el trasplante cardiaco. Rev Esp Cardiol. 1995;48 Supl 7:86-91.
91. Kemkes B, Schutz A, Engelhardt M, Brandl U, Breuer M. Noninvasive methods of rejection diagnosis after heart transplantation. J Heart Lung Transplant. 1992;11 (4 Pt 2):S221-31.
92. Sun J, Abdalla I, Asher C, Greenberg N, Popovic Z, Taylor D, et al. Non-invasive evaluation of orthotopic heart transplant rejection by echocardiography. J Heart Lung Transplant. 2005;24:160-5.
93. Dandel M, Hummel M, Muller J, Wellnhofer E, Meyer R, Solowjowa N, et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations. Circulation. 2001;104 Suppl 1:I184-91.
94. Evans R, Williams G, Baron H, Deng M, Eisen H, Hunt S, et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am J Transplant. 2005;5:1553-8.
95. Mehra M. The emergence of genomic and proteomic biomarkers in heart transplantation. J Heart Lung Transplant. 2005;24:S213-8.
96. Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6:150-60.
97. Kubo S, Naftel D, Mills RJ, O'Donnell J, Rodeheffer R, Cintron G, et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J Heart Lung Transplant. 1995;14:409-18.
98. Fyfe B, Loh E, Winters GL, Couper GS, Kartashov AI, Schoen FJ. Heart transplantation-associated perioperative ischemic myocardial injury. Morphological features and clinical significance. Circulation. 1996;93:1133-40.
99. Sheldon S, Hasleton P, Yonan N, Rhaman A, Deiraniya A, Campbell C, et al. Rejection in heart transplantation strongly correlates with HLA-DR antigen mismatch. Transplantation. 1994;58:719-22.
100. Jarcho J, Naftel D, Shroyer T, Kirklin J, Bourge R, Barr M, et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group. J Heart Lung Transplant. 1994;13:583-96.
101. Johnson M, Naftel D, Hobbs R, Kobashigawa J, Pitts D, Levine T, et al. The incremental risk of female sex in heart transplantation: a multiinstitutional study of peripartum cardiomyopathy and pregnancy. Cardiac Transplant Research Database Group. J Heart Lung Transplant. 1997;16:801-12.
102. Dew M, Kormos R, Roth L, Murali S, DiMartini A, Griffith B. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant. 1999;18:549-62.
103. Dobbels F, De Geest S, Van Cleemput J, Droogne W, Vanhaecke J. Effect of late medication non-compliance on outcome after heart transplantation: a 5-year follow-up. J Heart Lung Transplant. 2004;23:1245-51.
104. Rose A. Understanding the pathogenesis and the pathology of hyperacute cardiac rejection. Cardiovasc Pathol. 2002;11:171-6.
105. Agozzino L, Thomopoulos K, Esposito S, Agozzino M, De Vivo F, Maiello C, et al. Pathology of heart transplantation (morphological study of 1246 endomyocardial biopsies from 167 transplanted hearts). Causes of early, intermediate, and late deaths. Pathologica. 1999;91:89-100.
106. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989;8:430-43.
107. Fishbein M, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol. 2004;19:166-9.
108. Subherwal S, Kobashigawa J, Cogert G, Patel J, Espejo M, Oeser B. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. Transplant Proc. 2004;36:3171-2.
109. Michaels P, Espejo M, Kobashigawa J, Alejos J, Burch C, Takemoto S, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58-69.
110. Grauhan O, Knosalla C, Ewert R, Hummel M, Loeba M, Weng Y-G, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant. 2001;20:316-21.
111. Garrett HJ, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24:1337-42.
112. Aranda JJ, Scornik J, Normann S, Lottenberg R, Schofield R, Pauly D, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation. 2002;73:907-10.
113. Gulick T, Chung M, Pieper S, Lange L, Schreiner G. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A. 1989;86: 6753-7.
114. Hosenpud J, Campbell S, Mendelson D. Interleukin-1-induced myocardial depression in an isolated beating heart preparation. J Heart Transplant. 1989;8:460-4.
115. Sangrigoli R, Eisen H. Recovery of left ventricular function is more delayed in non-cellular rejection than cellular rejection. Circulation. 2000;102:11-817.
116. Lindenfeld J, Miller G, Shakar S, Zolty R, Lowes B, Wolfel E, et al. Drug therapy in the heart transplant recipient: Part I: cardiac rejection and immunosuppressive drugs. Circulation. 2004;110:3734-40.
117. Swinnen L, Costanzo-Nordin M, Fisher S, O'Sullivan E, Johnson M, Heroux A, et al. Increased incidence of lymphoproliferative disorder after inmunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med. 1990;323:1723-8.
118. Kirklin J, Bourge R, White-Williams C, Naftel D, Thomas F, Thomas J, et al. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3. J Thorac Cardiovasc Surg. 1990;99:716-24.
119. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corregido]. N Engl J Med. 1989;320:1420-1.
120. Hertz M, Boucek M, Deng M, Edwards L, Keck B, Kirklin J, et al. Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2005 annual reports. J Heart Lung Transplant. 2005;24:939-44.
121. Higgings R, Kirklin J, Brown R, Rayburn B, Wagoner L, Oren R, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant. 2005;24:392-400.
122. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke E, Groff B, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 2000;342:613-9.
123. Carlsen J, Johansen M, Boesgaard S, Andersen C, Arendrup H, Aldershvilet J, et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant. 2005;24:296-302.
124. Campos A, Lage E, Hinojosa R, Ordoñez A, Cisneros J, Cabezón S, et al. Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center. Transplant Proc. 2005;37:1548-9.
125. Amlot P, Rawlings E, Fernando O, Griffin P, Heinrich G, Schreier M, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995;60:748-56.
126. Kirkman R, Barrett L, Gaulton G, Kelley V, Ythier A, Strom T. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med. 1985;162:358-62.
127. Kahan B, Rajagopalan P, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999;67:276-84.
128. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gomez-Sanchez MA, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation. 2006;81:1542-8.
129. Lindenfeld J, Miller G, Shakar S, Zolty R, Lowes B, Wolfel E, et al. Drug therapy in the heart transplant recipient. Part II: Immunosuppressive Drugs. Circulation. 2004;110:3858-65.
130. Halloran P. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-29.
131. Borel J, Feurer C, Gubler H, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agent Actions. 1976;6:468-75.
132. Goto T, Kino T, Hatanaka H, Okuhara M, Kohsaka M, Aoki H, et al. FK506: Historical perspectives. Transplant Proc. 1991;23:2713-7.
133. Sarris GE, Moore KA, Schroeder JS, Hunt SA, Fowler MB, Valantine HB, et al. Cardiac transplantation: The Stanford experience in the cyclosporine era. J Thorac Cardiovasc Surg. 1994;108:240-52.
134. Robbins R, Barlow C, Oyer P, Hunt S, Miller J, Reitz B. Thirty years of cardiac transplantation at Stanford university. J Thorac Cardiovasc Surg. 1999;117:939-51.
135. Valantine H. Neoral use in the cardiac transplant recipient. Transplant Proc. 2000;32:S27-44.
136. Eisen H, Hobbs R, Davis S, Carrier M, Mancini D, Smith A, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine -results at 24 months after transplantation. Transplantation. 2001;71:70-8.
137. Ross H, Cantarovich M, Arizon J, Orus J, Straatman L, Howlett J, et al. A 12-month, multicenter, randomized, adaptive desing, open-label study to evaluate the benefit of C2-hr monitoring of neoral on safety and efficacy outcomes in the novo cardiac transplant recipients receiving Basiliximab induction: 6-month outcomes [resumen]. J Heart Lung Transplant. 2005;24 Suppl 2:S62.
138. Reichart B, Meiser B, Vigano M, Rinaldi M, Yacoub M, Banner R, et al. European multicenter tacrolimus heart pilot study: three year follow-up. J Heart Lung Transplant. 2001;20:249-50.
139. Taylor D, Barr M, Radovancevic B, Renlund D, Mentzer R, Smart F. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999;18:336-45.
140. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant. 2004;23:S202-6.
141. Grimm M, Rinaldi M, Yonan N, Arpesella G, Arizon Del Prado J, Pulpon L, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant. 2006;6:1387-97.
142. Eisen H, Tuzcu E, Dorent R, Kobashigawa J, Mancini D, Valantine von Kaeppler H, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplants recipients. N Engl J Med. 2003;349:847-58.
143. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694-700.
144. Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation. 1996;61:1661-2.
145. Ensley R, Bristow M, Olsen S, Taylor D, Hammond E, O'Connell J, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation. 1993;56:75-82.
146. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation. 1998;66:507-15.
147. Sánchez V, Delgado J, Blasco T, Dalmau R, Morales J, Escribano P, et al. Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy. Transplant Proc. 1999;31:2515-6.
148. Angermann C, Stork S, Costard-Jackle A, Dengler T, Siebert U, Tenderich G, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients, the IMPROVED multi-centre study. Eur Heart J. 2004;25:1626-34.
149. Groetzner J, Meiser B, Landwehr P, Buehse L, Mueller M, Kaczmarek I, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation. 2004;77:568-74.
150. Mardigyan V, Giannetti N, Cecere R, Besner J, Cantarovich M. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant. 2005;24:1614-8.
151. Pethig K, Heublein B, Wahlers T, Dannenberg O, Oppelt P, Haverich A. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant. 2004;23:61-6.
152. Kobashigawa J, Renlund D, Gerosa G, Almenar L, Eisen H, Keogh A, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant. 2006;25:935-41.
153. Vázquez de Prada J, Celemín I, De la Torre J, Rodríguez F, Sánchez N, Riesco F, et al. Corticosteroid withdrawal after heart transplantation. Transplant Proc. 1999;31:2212-4.
154. Laufer G, Laczkovics A, Wollenek G, Schreiner W, Wolner E. Results of orthotopic heart transplantation with and without the use of maintenance steroids. Eur J Cardiothorac Surg. 1988;2:237-43.
155. Livi U, Luciani G, Boffa G, Faggian G, Bortolotti U, Thiene G, et al. Clinical results of steroid-free induction immunosuppression after heart transplantation. Ann Thorac Surg. 1993;55:1160-5.
156. Keogh A, Macdonald P, Harvison A, Richens D, Mundy J, Spratt P. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation: two views of the steroid question. J Heart Lung Transplant. 1992;11(2 Pt 2):421-7.
157. Katz M, Barnhart G, Szentpetery S, Rider S, Thompson J, Hess M, et al. Are steroids essential for successful maintenance of immunosuppression in heart transplantation? J Heart Transplant. 1987;6:293-7.
158. Olivari M, Jessen M, Baldwin B, Horn V, Yancy C, Ring W, et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant. 1995;14(1 Pt 1):127-35.
159. Pritzker M, Lake K, Reutzel T, Hoffman F, Jorgensen C, Pederson W, et al. Steroid-free maintenance immunotherapy: Minneapolis Heart Institute experience. J Heart Lung Transplant. 1992;11(2 Pt 2):415-20.
160. Mehra M, Uber P, Park M, Ventura H, Scott R. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits. Transplant Proc. 2004;36:3152-5.
161. Tuzcu E, Kobashigawa J, Eisen H, Starling R, Crowe T, Abeywickrama J, et al. Favorable effect of everolimus on cardiac allograft vasculopathy is maintained through 24 months [resumen]. J Heart Lung Transplant. 2004;23 Suppl:S51.
162. Schmid C, Heemann U, Azuma H, Tilney N. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation. 1995;60:729-33.
163. Gregory C, Huang X, Pratt R, Dzau V, Shorthouse R, Billingham M, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995;59:655-61.
164. Poston R, Billingham M, Hoyt E, Pollard J, Shorthouse R, Morris R, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 1999;100:67-74.
165. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;107:1-6.
166. Segovia J, Alonso-Pulpón L, Ortiz P. RAPASTAT: Evaluation of the role of oral sirolimus in the treatment of established graft vessel disease: a prospective, randomized intravascular ultrasound study [resumen]. J Heart Lung Transplant. 2004;23 Suppl:S51-2.
167. Manito N, Kaplinsky E, Bernat R, Roca J, Castells E, Serrano T, et al. Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant. 2004;23:780-2.
168. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer H, Campistol J. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004;4:1869-75.
169. Snell G, Levvey B, Chin W, Kotsimbos T, Whitford H, Waters K, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant. 2002;21:540-6.
170. Kaplinsky E, Manito N, Roca J, Castells E, Saura E, Gomez-Hospital J, et al. Sirolimus in heart transplantation: a single center initial experience. Transplant Proc. 2003;35:1978-80.
171. Guba M, Von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine. 2002;8:128-135.
172. Guba M, Koehl G, Neppl E, Doenecke A, Steinbauer M, Schlitt H, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int. 2005;18:89-94.
173. Guba M, Yezhelyev M, Eichhorn M, Schmid G, Ischenko I, Papyan A, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005; 105:4463-9.
174. Luan F, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation. 2002;73:1565-72.
175. Koehl G, Andrassy J, Guba M, Richter S, Kroemer A, Scherer M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 2004;77:1319-26.
176. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A. 2000;97:4285-90.
177. Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75:1710-7.
178. Brown J, Murphy B, Douglas A, Short C, Bhatnagar D, Mackness M, et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron. 1997;75:277-82.
179. Morrisett J, Abdel-Fattah G, Kahan B. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc. 2003;35 Suppl 3:S143-50.
180. Reichart B, Meiser B, Vigano M, Rinaldi M, Martinelli L, Yacoub M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results. J Heart Lung Transplant. 1998;17:775-81.
181. Depczynski B, Daly B, Campbell L, Chisholm D, Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabetes Med. 2000;17:15-9.
182. Meiser B, Uberfuhr P, Fuchs A, Schmidt D, Pfeiffer M, Paulus D, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant. 1998;17:782-8.
183. Kobashigawa J. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant. 2003;22:711-4.
184. Easton J, Houghton P. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets. 2004;8:551-64.
185. Bechstein W. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13:313-26.
186. Costanzo M, Naftel D, Pritzker M, Heilman J, Boehmer J, Brozena S, et al. Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant. 1998;17:744-53.
187. Keogh A, Valantine H, Hunt S, et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 1992;11:892-901.
188. Cantin B, Gao S, Kwok B. Prognosis of patients with significant angiographically diagnosed cardiac allograft coronary disease [resumen]. J Heart Lung Transplant. 2002;Suppl 21:96.
189. Labarrere C, Nelson D, Cox C, Pitts D, Kirlin P, Halbrook H. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA. 2000;284:457-64.
190. Day J, Rayburn B, Gaudin P, Baldwin Wr, Lowenstein C, Kasper E, et al. Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant. 1995;14(6 Pt 2):S142-9.
191. Del Rizzo D, Menkis A, Pflugfelder P, Novick R, McKenzie F, Boyd W, et al. The role of donor age and ischemic time on survival following orthotopic heart transplantation. J Heart Lung Transplant. 1999;18:310-9.
192. Hosenpud J, Morris T, Shipley G, Mauck K, Wagner C. Cardiac allograft vasculopathy. Preferential regulation of endothelial cell-derived mesenchymal growth factors in response to a donor-specific cell-mediated allogeneic response. Transplantation. 1996;61:939-48.
193. Behrendt D, Ganz P, Fang J. Cardiac allograft vasculopathy. Curr Opin Cardiol. 2000;15:422-9.
194. Aranda JJ, Hill J. Cardiac transplant vasculopathy. Chest. 2000;118:1792-800.
195. Aziz T, Hasleton P, Hann A, Yonan N, Deiraniya A, Hutchinson I. Transforming growth factor beta in relation to cardiac allograft vasculopathy after heart transplantation. J Thorac Cardiovasc Surg. 2000;119(4 Pt 1):700-8.
196. Holweg C, Baan C, Balk A, Niesters H, Maat A, Mulder P, et al. The transforming growth factor-beta1 codon 10 gene polymorphism and accelerated graft vascular disease after clinical heart transplantation. Transplantation. 2001;71:1463-7.
197. Fredrich R, Toyoda M, Czer L, Galfayan K, Galera O, Trento A, et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation. 1999;67:385-91.
198. Wheeler C, Collins A, Dunn M, Crisp S, Yacoub M, Rose M. Characterization of endothelial antigens associated with transplant-associated coronary artery disease. J Heart Lung Transplant. 1995;14(6 Pt 2):S188-97.
199. Jurcevic S, Ainsworth M, Pomerance A, Smith J, Robinson D, Dunn M, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation. 2001;71:886-92.
200. Hornick P, Smith J, Pomerance A, Mitchell A, Banner N, Rose M, et al. Influence of acute rejection episodes, HLA matching, and donor/recipient phenotype on the development of 'early' transplant-associated coronary artery disease. Circulation. 1997;96 Suppl 9:II148-53.
201. Mulla N, Johnston J, Vander Dussen L, Beeson W, Chinnock R, Bailey L, et al. Late rejection is a predictor of transplant coronary artery disease in children. J Am Coll Cardiol. 2001;37:243-50.
202. Jimenez J, Kapadia S, Yamani M, Platt L, Hobbs R, Rincon G, et al. Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant. 2001;20:393-8.
203. Hosenpud J, Bennett L, Keck B, Boucek M, Novick R. The Registry of the International Society for Heart and Lung Transplantation: eighteenth official report 2001. J Heart Lung Transplant. 2001;20:805-15.
204. Aziz T, Burgess M, Rahman A, Campbell C, Yonan N. Cardiac transplantation for cardiomyopathy and ischemic heart disease: differences in outcome up to 10 years. J Heart Lung Transplant. 2001;20:525-33.
205. John R, Rajasinghe H, Itescu S, Suratwalla S, Lietz K, Weinberg A, et al. Factors affecting long-term survival (> 10 years) after cardiac transplantation in the cyclosporine era. J Am Coll Cardiol. 2001;37:189-94.
206. Escobar A, Ventura H, Stapleton D, Mehra M, Ramee S, Collins T, et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol. 1994;74:1042-6.
207. Pethig K, Klauss V, Heublein B, Mudra H, Westphal A, Weber C, et al. Progression of cardiac allograft vascular disease as assessed by serial intravascular ultrasound: correlation to immunological and non-immunological risk factors. Heart. 2000;84:494-8.
208. Kapadia S, Nissen S, Ziada K, Rincon G, Crowe T, Boparai N, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol. 2001;38:206-13.
209. Hosenpud J. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am Heart J. 1999;138(5 Pt 2):S469-72.
210. Shirali G, Ni J, Chinnock R, Johnston J, Rosenthal G, Bowles N, et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med. 2001;344:1498-503.
211. Hauptman P, O'Connor K, Wolf R, McNeil B. Angiography of potential cardiac donors. J Am Coll Cardiol. 2001;37:1252-8.
212. Botas J, Pinto F, Chenzbraun A, Liang D, Schroeder J, Oesterle S, et al. Influence of preexistent donor coronary artery disease on the progression of transplant vasculopathy. An intravascular ultrasound study. Circulation. 1995;92:1126-32.
213. Spes C, Klauss V, Mudra H, Schnaack S, Tammen A, Rieber J, et al. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy. A comparson with coronary angiography and intravascular ultrasound. Circulation. 1999;100:509-15.
214. Derumeaux G, Redonnet M, Mouton-Schleifer D, Bessou J, Cribier A, Saoudi N, et al. Dobutamine stress echocardiography in orthotopic heart transplant recipients. VACOMED Research Group. J Am Coll Cardiol. 1995;25:1665-72.
215. Spes C, Mudra H, Schnaack S, Klauss V, Reichle F, Uberfuhr P, et al. Dobutamine stress echocardiography for noninvasive diagnosis of cardiac allograft vasculopathy: a comparison with angiography and intravascular ultrasound. Am J Cardiol. 1996;78:168-74.
216. Elhendy A, Sozzi F, Van-Domburg R, Vantrimpont P, Valkema R, Krenning E, et al. Accuracy of dobutamine tetrofosmin myocardial perfusion imaging for the noninvasive diagnosis of transplant coronary artery stenosis. J Heart Lung Transplant. 2000;19:360-6.
217. Rodney R, Johnson L, Blood D, Barr M. Myocardial perfusion scintigraphy in heart transplant recipients with and without allograft atherosclerosis: a comparison of thallium-201 and technetium 99m sestamibi. J Heart Lung Transplant. 1994;13:173-80.
218. Elhendy A, Van Domburg R, Vantrimpont P, Poldermans D, Bax J, Van Gelder T, et al. Prediction of mortality in heart transplant recipients by stress technetium-99m tetrofosmin myocardial perfusion imaging. Am J Cardiol. 2002;89:964-8.
219. Flox A, Sanchez V, Delgado J, Fernandez S, Tello R, Jimenez J, et al. Is atropine infusion necessary to achieve the target heart rate in heart transplant patients during dobutamine stress echocardiography? Transplant Proc. 2002;34:3241-2.
220. Ehrman J, Keteyian S, Levine A, Rhoads K, Elder L, Levine T, et al. Exercise stress tests after cardiac transplantation. Am J Cardiol. 1993;71:1372-3.
221. Pope S, Stinson E, Daughters Gn, Schroeder J, Ingels NJ, Alderman E. Exercise response of the denervated heart in long-term cardiac transplant recipients. Am J Cardiol. 1980;46:213-8.
222. Lazem F, Barbir M, Banner N, Ludman P, Mitchell A, Yacoub M. Coronary calcification detected by ultrafast computed tomography is a predictor of cardiac events in heart transplant recipients. Transplant Proc. 1997;29:572-5.
223. Knollmann F, Bocksch W, Spiegelsberger S, Hetzer R, Felix R, Hummel M. Electron-beam computed tomography in the assessment of coronary artery disease after heart transplantation. Circulation. 2000;101:2078-82.
224. Ratliff NR, Jorgensen C, Gobel F, Hodges M, Knickelbine T, Pritzker M. Lack of usefulness of electron beam computed tomography for detecting coronary allograft vasculopathy. Am J Cardiol. 2004;94:202-6.
225. Al-Saadi N, Nagel E, Gross M, Bornstedt A, Schnackenburg B, Klein C, et al. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation. 2000;101:1379-83.
226. Muehling O, Wilke N, Panse P, Jerosch-Herold M, Wilson B, Wilson R, et al. Reduced myocardial perfusion reserve and transmural perfusion gradient in heart transplant arteriopathy assessed by magnetic resonance imaging. J Am Coll Cardiol. 2003;42:1054-60.
227. Gao S, Alderman E, Schroder J, Silverman J, Hunt S. Accelerated coronary artery disease in heart transplant patients: coronary arteriographic findings. J Am Coll Cardiol. 1988;12:334-40.
228. Clague J, Cox I, Murday A, Charokopos N, Madden B. Low clinical utility of routine angiographic surveillance in the detection and management of cardiac allograft vasculopathy in transplant recipients. Clin Cardiol. 2001;24:459-62.
229. Sharples L, Jackson C, Parameshwar J, Wallwork J, Large S. Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy. Transplantation. 2003;76:679-82.
230. Johnson D, Alderman E, Schroeder J, Gao S, Hunt S, DeCampli W, et al. Transplant coronary artery disease: histopathologic correlations with angiographic morphology. J Am Coll Cardiol. 1991;17:449-57.
231. St Goar F, Pinto F, Alderman E, Valantine H, Schroeder J, Gao S, et al. Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening. Circulation. 1992;85:979-87.
232. Rickenbacher P, Pinto F, Chenzbraun A, Botas J, Lewis N, Alderman E, et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol. 1995;25:171-7.
233. Rickenbacher P, Pinto F, Lewis N, Hunt S, Alderman E, Schroeder J, et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation. 1995;92:3445-52.
234. Kobashigawa J, Tobis J, Starling R, Tuzcu E, Smith A, Valantine H, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45:1532-7.
235. Kofoed K, Czernin J, Johnson J, Kobashigawa J, Phelps M, Laks H, et al. Effects of cardiac allograft vasculopathy on myocardial blood flow, vasodilatory capacity, and coronary vasomotion. Circulation. 1997;95:600-6.
236. Hollenberg S, Klein L, Parrillo J, Scherer M, Burns D, Tamburro P, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation. 2001;104:3091-6.
237. Hollenberg S, Klein L, Parrillo J, Scherer M, Burns D, Tamburro P, et al. Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. J Heart Lung Transplant. 2004;23:265-71.
238. Klauss V, Spes C, Rieber J, Siebert U, Werner F, Stempfle H, et al. Predictors of reduced coronary flow reserve in heart transplant recipients without angiographically significant coronary artery disease. Transplantation. 1999;68:1477-81.
239. Fearon W, Nakamura M, Lee D, Rezaee M, Vagelos R, Hunt S, et al. Simultaneous assessment of fractional and coronary flow reserves in cardiac transplant recipients: Physiologic Investigation for Transplant Arteriopathy (PITA Study). Circulation. 2003;108:1605-10.
240. Mehra M, Ventura H, Smart F, Stapleton D, Collins T, Ramee S, et al. New developments in the diagnosis and management of cardiac allograft vasculopathy. Tex Heart Inst J. 1995;22:138-44.
241. Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med. 2000;1:166-71.
242. Mehra M, Ventura H, Smart F, Collins T, Ramee S, Stapleton D. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol. 1995;75:853-4.
243. Kobayashi J, Crawford S, Backer C, Zales V, Takami H, Hsueh C, et al. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation. 1993;88(5 Pt 2):II286-90.
244. Richter M, Skupin M, Grabs R, Schramm D, Richter H, Olbrich H. New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model. J Heart Lung Transplant. 2000;19:1047-55.
245. Schroeder JS, Gao S-Z, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 1993;328:164-70.
246. Atkinson J, Wudel J, Hoff S, Stewart J, Frist W. Amlodipine reduces graft coronary artery disease in rat heterotopic cardiac allografts. J Heart Lung Transplant. 1993;12:1036-44.
247. Weis M, Pehlivanli S, Von Scheidt W. Vasodilator response to nifedipine in human coronary arteries with endothelial dysfunction. J Cardiovasc Pharmacol. 2002;39:172-80.
248. Valantine H. The role of viruses in cardiac allograft vasculopathy. Am J Transplant. 2004;4:169-77.
249. Weis M, Kledal T, Lin K, Panchal S, Gao S, Valantine H, et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation. 2004;109:500-5.
250. Petrakopoulou P, Kubrich M, Pehlivanli S, Meiser B, Reichart B, Von Scheidt W, et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation. 2004;110 Suppl 1:II207-12.
251. Valantine H, Gao S, Menon S, Renlund D, Hunt S, Oyer P, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation. 1999;100:61-6.
252. Valantine H, Luikart H, Doyle R, Theodore J, Hunt S, Oyer P, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation. 2001;72:1647-52.
253. Luckraz H, Charman S, Wreghitt T, Wallwork J, Parameshwar J, Large S. Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era? J Heart Lung Transplant. 2003;22:1023-7.
254. Griepp R, Stinson E, Bieber C, Reitz B, Copeland J, Oyer P, et al. Control of graft arteriosclerosis in human heart transplant recipients. Surgery. 1977;81:262-9.
255. Aziz S, Tada Y, Gordon D, McDonald T, Fareed J, Verrier E. A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. J Heart Lung Transplant. 1993;12:634-43.
256. Wenke K, Meiser B, Thiery J, Nagel D, Von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial. Circulation. 1997;96:1398-402.
257. Mehra M, Raval N. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc. 2004;36:1539-41.
258. Klauss V, Konig A, Spes C, Meiser B, Rieber J, Siebert U, et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol. 2000;85:266-9.
259. Petrakopoulou P, Anthopoulou L, Muscholl M, Klauss V, Von Scheidt W, Uberfuhr P, et al. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. J Am Coll Cardiol. 2006;47:1622-9.
260. Kobashigawa J, Tobis J, Mentzer R, Valantine H, Bourge R, Mehra M, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant. 2006;6:993-7.
261. Hosenpud J, Bennet L. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the joint UNOS/ISHLT thoracic registry. Transplantation. 2001;72:1662-5.
262. Segovia J. Update on cardiac allograft vasculopathy. Curr Opin Organ Transplant. 2002;7:240-51.
263. Pinney S, Mancini D. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr Opin Cardiol. 2004;19:170-6.
264. Sandhu J, Uretsky B, Reddy P, Denys B, Ruffner R, Breisblatt W, et al. Potential limitations of percutaneous transluminal coronary angioplasty in heart transplant recipients. Am J Cardiol. 1992;69:1234-7.
265. Parry A, Roberts M, Parameshwar J, Wallwork J, Schofield P, Large S. The management of post-cardiac transplantation coronary artery disease. Eur J Cardiothorac Surg. 1996;10:528-32.
266. Wong P, Piamsomboon C, Mathur A, Chastain Hn, Singh D, Liu M, et al. Efficacy of coronary stenting in the management of cardiac allograft vasculopathy. Am J Cardiol. 1998;82:239-40.
267. Marelli M, Rabago G, Calabuig J, Martinez Caro D, Coma-Canella I, Martin Trenor A. Midterm results of percutaneous transluminal coronary angioplasty in graft coronary artery disease in cardiac transplant patients. Transplant Proc. 1999;31:2539-41.
268. Benza R, Zoghbi G, Tallaj J, Brown R, Kirklin J, Hubbard M, et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol. 2004;43:1973-81.
269. Weston M, Spoto EJ, Sommers E, Sears N, Novitzky D. Stenting unprotected left main coronary artery stenosis in heart transplant patients -the good, bad, and the ugly. J Heart Lung Transplant. 2001;20:1228-32.
270. Chan A, Carere R, Khatri S, Della Siega A, Ignaszewski A, Webb J. Unprotected left main coronary artery stenting for cardiac allograft vasculopathy. J Heart Lung Transplant. 2001;20:776-80.
271. De Gevigney G, Roriz R, MacFadden E, Boissonnat P, Chuzel M, Gare J, et al. Should we still perform angioplasty and stenting of an unprotected left main coronary artery stenosis in heart transplant patients? Two new cases and a review of the literature. J Heart Lung Transplant. 2001;20:1217-9.
272. Koyanagi T, Kyo S, Ouchi H, Asano H, Yokote Y, Omoto R. Combined coronary intervention in heart-transplant patient with rapidly accelerated cardiac allograft vasculopathy. Jpn J Thorac Cardiovasc Surg. 2001;49:117-21.
273. Sousa J, Costa M, Abizaid A, Rensing B, Abizaid A, Tanajura L, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-11.
274. Klauss V, Stempfle H, Theisen K, Kantlehner R, Poellinger B, Reichart B, et al. Vascular brachytherapy for treatment of cardiac allograft vasculopathy. J Heart Lung Transplant. 2001;20:792-4.
275. Musci M, Loebe M, Wellnhofer E, Meyer R, Pasic M, Hummel M, et al. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Thorac Cardiovasc Surg. 1998;46:268-74.
276. Halle Ar, DiSciascio G, Massin E, Wilson R, Johnson M, Sullivan H, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol. 1995;26:120-8.
277. Miller L, Donohue T, Wolford T. The surgical management of allograft coronary disease: a paradigm shift. Sem Thorac Cardiovasc Surg. 1996;8:133-8.
278. Benza R, Tallaj J. Cardiac allograft vasculopathy (chronic rejection). En: Kirklin J, Young J, McGiffin D, editores. Heart transplantation. New York: Churchill Livingstone; 2002. p. 615-65.
279. Smith J, Rivakove G, Hunt S, et al. Heart retransplantation the 25 year experience at a single institution. J Heart Lung Transplant. 1995;14:832-9.
280. Dearani J, Razzouk A, Gundry S, Chinnock R, Larsen R, Del Rio M, et al. Pediatric cardiac retransplantation: intermediate-term results. Ann Thorac Surg. 2001;71:66-70.
281. Rayburn B. Other long-term complications. En: Kirklin J, Young J, McGiffin D, editores. Heart transplantation. Philadelphia: Churchill Livingstone; 2002. p. 666-702.
282. Herlitz H, Lindelow B. Renal failure following cardiac transplantation. Nephrol Dial Transplant. 2000;15:311-4.
283. Rubel J, Milford E, McKay D, Jarcho J. Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant. 2004;23:289-300.
284. Senechal M, Dorent R, Du Montcel S, Ghossou J, Pavie A, Petitclerc T, et al. End-stage renal failure and cardiac mortality after heart transplantation. Clin Transplant. 2004;18:1-6.
285. Chan C, Maurer J, Cardella C, Cattran D, Pei Y. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation. 1997;63:1435-40.
286. Sehgal V, Radhakrishnan J, Appel G, Valeri A, Cohen D. Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension. Am J Kidney Dis. 1995;26:193-201.
287. Fernandez-Valls M, Gonzalez-Vilchez F, De Prada J, Ruano J, Ruisanchez C, Martin-Duran R. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center. Transplant Proc. 2005;37:4021-3.
288. Bellet M, Cabrol C, Sassano P, Leger P, Corvol P, Menard J. Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system. Am J Cardiol. 1985;56:927-31.
289. McKoy R, Uretsky B, Kormos R, Hardesty R, Griffith B, Salerni R. Left ventricular hypertrophy in cyclosporine-induced systemic hypertension after cardiac transplantation. Am J Cardiol. 1988;62:1140-2.
290. Pham S, Kormos R, Hattler B, Kawai A, Tsamandas A, Demetris A, et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-terms results. J Thorac Cardiovasc Surg. 1996;111:764-72.
291. Ray J, Keogh A, McLachlan A, Akhlaghi F. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant. 2003;22:715-22.
292. Brozena S, Johnson M, Ventura H. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trial. J Am Coll Cardiol. 1996;26:1707-12.
293. Dantal J, Soulillou J. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005;352:1371-3.
294. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55:742-7.
295. Edwards B, Hunt S, Fowler M, Valantine H, Stinson E, Schroeder J. Cardiac transplantation in patients with preexisting neoplastic diseases. Am J Cardiol. 1990;65:501-4.
296. Wilson R, Penn I. Fate of tumors transplanted with a renal allograft. Transplant Proc. 1975;7:327-31.
297. Pedotti P, Poli F, Longhi E, Frison S, Caldara R, Chiaramonte S, et al. Epidemiologic study on the origin of cancer after kidney transplantation. Transplantation. 2004;77:426-8.
298. Hunt S. Malignancy in organ tansplantation: heart. Transpl Proc. 2002;34:1874-6.
299. Crespo-Leiro M, Pulpón L, Arizón J, Almenar L, Delgado J, Palomo J, et al. Incidence, type and prognosis of malignancy alter heart transplantation. Data from the Spanish post-(Heart Transplant) Tumors Registry [resumen]. J Heart Lung Transplant. 2006;25 Suppl 2:S121-2.
300. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222-30.
301. Swerdlow A, Higgins G, Hunt B, Thomas J, Burike M, Crawford D, et al. Risk of lymphoid neoplasia after cardiothoracic transplantation. a cohort study of the relation to Epstein-Barr virus. Transplantation. 2000;69:897-904.
302. Burgert S, Strickman N, Carrol C, Falcone M. Cardiac Kaposi's sarcoma following heart transplantation. Catheter Cardiovasc Interv. 2000;49:208-12.
303. Briz M, Alonso-Pulpón L, Crespo-Leiro M, et al. Detection of herpesvirus-like sequences in Kaposi's sarcoma from heart transplant recipients. J Heart Lung Transplant. 1998;17:288-93.
304. Anyanwu A, Townsend E, Banner N, Burke M, Khaghani A, Yacoub M. Primary lung carcinoma after heart or lung transplantation: management and outcome. J Thorac Cardiovasc Surg. 2002;124:1190-7.
305. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317-23.
306. Mackintosh A, Carmichael D, Wren C, Cory-Pearce R, English T. Sinus node function in first three weeks after cardiac transplantation. Br Heart J. 1982;48:584-8.
307. Raghavan C, Maloney J, Nitta J, Lowry R, Saliba W, Cocanougher B, et al. Long-term follow-up of heart transplant recipients requiring permanent pacemakers. J Heart Lung Transplant. 1995;14(6 Pt 1):1081-9.
308. Miyamoto Y, Curtiss E, Kormos R, Armitage J, Hardesty R, Griffith B. Bradyarrhythmia after heart transplantation. Incidence, time course, and outcome. Circulation 1990;82 Suppl 5:V313-7.
309. Redmond J, Zehr K, Gillinov M, Baughman K, Augustine S, Cameron D, et al. Use of theophylline for treatment of prolonged sinus node dysfunction in human orthotopic heart transplantation. J Heart Lung Tranplant. 1993;12(1 Pt 1):133-8.
310. Heinz G, Kratochwill C, Buxbaum P, Laufer G, Kreiner G, Siostrzonek P,
311. Scott C, Dark J, McComb J. Sinus node function after cardiac transplantation. J Am Coll Cardiol. 1994;24:1334-41.
312. Melton I, Gilligan D, Wood M, Ellenbogen K. Optimal cardiac pacing after heart transplantation. Pacing Clin Electrophysiol. 1999;22:1510-27.
313. Little R, Kay G, Epstein A, Plumb V, Bourge R, Neves J, et al. Arrhythmias after orthotopic cardiac transplantation. Prevalence and determinants during initial hospitalization and late followup. Circulation. 1989;80(5 Pt 2):III140-6.
314. Pavri B, O'Nunain S, Newell J, Ruskin J, William G. Prevalence and prognostic significance of atrial arrhythmias after orthotopic cardiac transplantation. J Am Coll Cardiol. 1995;25:1673-80.
315. Arenal A, Almendral J, Munoz R, Villacastin J, Merino J, Palomo J, et al. Mechanism and location of atrial flutter in transplanted hearts: observations during transient entrainment from distant sites. J Am Coll Cardiol. 1997;30:539-46.
316. Ahmari S, Bunch T, Chandra A, Chandra V, Ujino K, Daly R, et al. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter. J Heart Lung Transplant. 2006;25:53-60.
317. Khan M, Kalahasti V, Rajagopal V, Khaykin Y, Wazni O, Almahameed S, et al. Incidence of atrial fibrillation in heart transplant patients: long-term follow-up. J Cardiovasc Electrophysiol. 2006;17:827-31.
318. Ptaszek L, Wang P, Hunt S, Valantine H, Perlroth M, Al-Ahmad A. Use of the implantable cardioverter-defibrillator in long-term survivors of orthotopic heart transplantation. Heart Rhythm. 2005;2:931-3.
319. Patel V, Lim M, Massin E, Jonsyn G, Ates P, Abou-Awdi N, et al. Sudden cardiac death in cardiac transplant recipients. Circulation. 1996;94 Suppl 9:II273-7.
320. Kasiske B, Snyder J, Gilbertson D, Matas A. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-85.
321. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant. 2004;23 Suppl 5:S194-201.
322. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75 Suppl 10:S3-24.
323. Thomas C, Limper A. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-98.
324. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-20.
325. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis. 2005;40:704-8.
326. Aguado J, Gomez-Sanchez M, Lumbreras C, Delgado J, Lizasoain M, Otero J, et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother. 1995;39:1643-5.
327. Paniagua MJ, Crespo-Leiro MG, De la Fuente L, Tabuyo T, Mosquera I, Canizares A, et al. Prevention of cytomegalovirus disease after heart transplantation: preemptive therapy with 7 days' intravenous ganciclovir. Transplant Proc. 2002;34:69-70.
328. Ayats-Ardite J, Cisneros-Herreros J, Pérez-Sáenz J, Torre-Cisneros J. Evaluación de las enfermedades infecciosas en el candidato a trasplante de órganos sólidos. Enferm Infecc Microbiol Clin. 2002;20:448-61.
329. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J. 2004;25:267-76.
330. Sherman-Weber S, Axelrod P, Suh B, Rubin S, Beltramo D, Manacchio J, et al. Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. Transpl Infect Dis. 2004;6:165-70.
331. Shane E, Mancini D, Aaronson K, Silverberg S, Seibel M, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
332. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001;357:342-7.
333. Boncimino K, McMahon D, Addesso V, Bilezikian J, Shane E. Magnesium deficiency and bone loss after cardiac transplantation. J Bone Miner Res. 1999;14:295-303.
334. Shane E, Rodino M, McMahon D, Addesso V, Staron R, Seibel M, et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant. 1998;17:1089-96.
335. Pisani B, Mullen G. Prevention of osteoporosis in cardiac transplant recipients. Curr Opin Cardiol. 2002;17:160-4.
336. Reid I, King A, Alexander C, Ibbertson H. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988;1:143-6.
337. Van Cleemput J, Daenen W, Geusens P, Dequeker P, Van De Werf F, VanHaecke J. Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Transplantation. 1996;61:1495-9.
338. Trombetti A, Gerbase M, Spiliopoulos A, Slosman D, Nicod L, Rizzoli R. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant. 2000;19:736-43.
339. Shane E, Addesso V, Namerow P, McMahon D, Lo S, Staron R, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004;350:767-76.
340. Braith R, Mills R, Welsch M, Keller J, Pollock M. Resistance exercise training restores bone mineral density in heart transplant recipients. J Am Coll Cardiol. 1996;28:1471-7.
341. Boucek M, Mathis C, Razzouk A, Gundry S, Bailey L, Fullerton D, et al. Indications and contraindications for heart transplantation in infancy. J Heart Lung Transplant. 1993;12(6 Pt 2):S154-8.
342. Boucek M, Waltz D, Edwards L, Taylor D, Keck B, Trulock E, et al. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report -2006. J Heart Lung Transplant. 2006;25:893-903.
343. Maroto C, Enríquez de Salamanca F, Herraiz J, Zabala J. Guías de práctica clínica de la Sociedad Española de Cardiología en las cardiopatías congénitas más frecuentes. Rev Esp Cardiol. 2001;54:67-82.
344. Tsirka A, Trinkaus K, Chen S, Lipshultz S, Towbin J, Colan S, et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol. 2004;44:391-7.
345. Coutu M, Perrault L, White M, Pelletier G, Racine N, Poirier N, et al. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. J Heart Lung Transplant. 2004;23:413-7.
346. Gajarski R, Mosca R, Ohye R, Bove E, Crowley D, Custer J, et al. Use of extracorporeal life support as a bridge to pediatric cardiac transplantation. J Heart Lung Transplant. 2003;22:28-34.
347. Poirier N, Yu J, Brizard C, Mee R. Long-term results of left ventricular reconditioning and anatomic correction for systemic right ventricular dysfunction after atrial switch procedures. J Thorac Cardiovasc Surg. 2004;127:975-81.
348. Jayakumar K, Addonizio L, Kichuk-Chrisant M, Galantowicz M, Lamour J, Quaegebeur J, et al. Cardiac transplantation after the Fontan or Glenn procedure. J Am Coll Cardiol. 2004;44:2065-72.
349. Alonso-Pulpón L, Almenar L, Crespo M, Silva L, Segovia J, Manito N, et al. Guías de actuación clínica de la Sociedad Española de Cardiología. Trasplante cardíaco y de corazón-pulmones. Rev Esp Cardiol. 1999;52:821-39.
350. Chinoock R, Pearce F. Pediatric transplantation. En: Kirklin J, Young J, McGiffin D, editores. Heart transplantation. New York: Churchill Livingstone; 2001. p. 760-1.
351. Dellgren G, Coles J. Pediatric heart transplantation: improving results in high-risk patients. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2001;4:103-14.
352. Ranjit J. Donor management and selection for heart transplantation. Semin Thorac Cardiovasc Surg. 2004;16:364-9.
353. Bennett L, Edwards E, Hosenpud J. Transplantation with older donor hearts for presumed "stable" recipients: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant. 1998;17:901-5.
354. West LJ, Pollock-Barziv S, Dipchand AI, Lee KJ, Cardella CJ, Benson LN, et al. ABO-incompatible heart transplantation in infants. N Engl J Med. 2001;11: 793-800.
355. Kapoor A, Laks H. Atlas of heart-lung transplantation. New York: McGraw-Hill; 1994.
356. Aziz T, Burgess M, Khafagy R, Wynn Hann A, Campbell C, Rahman A, et al. Bicaval and standard techniques in orthotopic heart transplantation: medium-term experience in cardiac performance and survival. J Thorac Cardiovasc Surg. 1999;118:115-22.
357. Shumway N, Lower R, Stofer R. Transplantation of the heart. Adv Surg. 1966;2:265-84.
358. Backer C, Idriss F, Zales V, Mavroudis C. Cardiac transplantation for hypoplastic left heart syndrome: a modified technique. Ann Thorac Surg. 1990;50:894-8.
359. Rosenthal D, Chrisant M, Edens E, Mahony L, Canter C, Colan S, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant. 2004;23:1313-33.
360. Jaggers J, Forbess J, Shah A, Meliones J, Kirshbom P, Miller C, et al. Extracorporeal membrane oxygenation for infant postcardiotomy support: significance of shunt management. Ann Thorac Surg. 2000;69:1476-83.
361. Webber S, Naftel D, Parker J, Mulla N, Balfour I, Kirklin J, et al. Late rejection episodes more than 1 year after pediatric heart transplantation: risk factors and outcomes. J Heart Lung Transplant. 2003;22:869-75.
362. Wagner K, Oliver M, Boyle G, Miller S, Law Y, Pigula F, et al. Endomyocardial biopsy in pediatric heart transplant recipients: a useful exercise? (Analysis of 1,169 biopsies). Pediatr Transplant. 2000;4:186-92.
363. Pophal S, Sigfusson G, Booth K, Bacanu S, Webber S, Ettedgui J, et al. Complications of endomyocardial biopsy in children. J Am Coll Cardiol. 1999;34:2105-10.
364. Kuhn M, Deming D, Cephus C, Mulla N, Chinnock R, Razzouk A, et al. Moderate acute rejection detected during annual catheterization in pediatric heart transplant recipients. J Heart Lung Transplant. 2003;22:276-80.
365. Boucek M, Mathis C, Boucek RJ, Hodgkin D, Kanakriyeh M, McCormack J, et al. Prospective evaluation of echocardiography for primary rejection surveillance after infant heart transplantation: comparison with endomyocardial biopsy. J Heart Lung Transplant. 1994;13(1 Pt 1):66-73.
366. Reddy SC, Laughlin K, Webber SA. Immunosuppression in Pediatric Heart Transplantation: 2003 and Beyond. Curr Treat Options Cardiovasc Med. 2003;5:417-28.
367. Asano M, Gundry S, Razzouk A, Del Rio M, Thomas M, Chinnock R, et al. Total lymphoid irradiation for refractory rejection in pediatric heart transplantation. Ann Thorac Surg. 2002;74:1979-85.
368. McGhee B, McCombs J, Boyle G, Webber S, Reyes J. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. Transplantation. 1997;64:941-2.
369. Dipchand A, Benson L, McCrindle B, Coles J, West L. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant. 2001;5:112-8.
370. Schubert M, Venkataramanan R, Holt D, Shaw L, McGhee W, Reyes J, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant. 2004;4:767-73.
371. Parisi F, Danesi H, Squitieri C, Di Chiara L, Rava L, Di Donato R. Thymoglobuline use in pediatric heart transplantation. J Heart Lung Transplant. 2003;22:591-3.
372. Boucek M, Edwards L, Keck B, Trulock E, Taylor D, Hertz M. Registry of the International Society for Heart and Lung Transplantation: eighth official pediatric report -2005. J Heart Lung Transplant. 2005;24:968-82.
373. Dent C, Canter C, Hirsch R, Balzer D. Transplant coronary artery disease in pediatric heart transplant recipients. J Heart Lung Transplant. 2000;19:240-8.
374. Costello J, Wax D, Binns H, Backer C, Mavroudis C, Pahl E. A comparison of intravascular ultrasound with coronary angiography for evaluation of transplant coronary disease in pediatric heart transplant recipients. J Heart Lung Transplant. 2003;22:44-9.
375. Sigfusson G, Fricker F, Bernstein D, Addonizio L, Baum D, Hsu D, et al. Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children who have survived longer than five years. J Pediatr. 1997;130:862-71.
376. Kuhn M, Jutzy K, Deming D, Cephus C, Chinnock R, Johnston J, et al. The medium-term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation. J Am Coll Cardiol. 2000;36:250-4.
377. Mahle W, Vincent R, Berg A, Kanter K. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant. 2005;24:63-6.
378. Mahle W, Vincent R, Kanter K. Cardiac retransplantation in childhood: analysis of data from the United Network for Organ Sharing. J Thorac Cardiovasc Surg. 2005;130:542-6.
379. Pahl E, Crawford S, Swenson J, Duffy C, Fricker F, Backer C, et al. Dobutamine stress echocardiography: experience in pediatric heart transplant recipients. J Heart Lung Transplant. 1999;18:725-32.
380. Lamich R, Ballester M, Marti V, Brossa V, Aymat R, Carrio I, et al. Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. J Am Coll Cardiol. 1998;32:413-9.
381. Hornung T, De Goede C, O'Brien C, Moghal N, Dark J, O'Sullivan F. Renal function after pediatric cardiac transplantation: the effect of early cyclosporin dosage. Pediatrics. 2001;107:1346-50.
382. Alonso E. Long-term renal function in pediatric liver and heart recipients. Pediatr Transplant. 2004;8:381-5.
383. Henne T, Latta K, Strehlau J, Pape L, Ehrich J, Offner G. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation. 2003;76:1326-30.
384. Lobach N, Pollock-Barziv S, West L, Dipchand A. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant. 2005;24:184-9.
385. Hathout E, Chinnock R, Johnston J, Fitts J, Razzouk A, Mace J, et al. Pediatric post-transplant diabetes: data from a large cohort of pediatric heart-transplant recipients. Am J Transplant. 2003;3:994-8.
386. Paolillo J, Boyle G, Law Y, Miller S, Lawrence K, Wagner K, et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. Transplantation. 2001;71:252-6.
387. Zangwill S, Hsu D, Kichuk M, Garvin J, Stolar C, Haddad J, et al. The incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant. 1998;17:1161-8.
388. Herman J, Vandenberghe P, Van den Heuvel I, Van Cleemput J, Winnepenninckx V, Van Damme-Lombaerts R. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation. J Heart Lung Transplant. 2002; 202:1304-9.
389. Saland J. Osseous complications of pediatric transplantation. Pediatr Transplantation. 2004;8:400-15.
390. Comité Asesor de Vacunas. Calendario vacunal de la Asociación Española de Pediatría 2005. An Pediatr (Barc). 2005;62:158-60.
391. a ed. AAP; 2003. p. 84.